Share This Page
Drug Price Trends for NDC 62135-0745
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0745
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VERAPAMIL 120 MG TABLET | 62135-0745-90 | 0.08606 | EACH | 2025-12-17 |
| VERAPAMIL 120 MG TABLET | 62135-0745-90 | 0.08535 | EACH | 2025-11-19 |
| VERAPAMIL 120 MG TABLET | 62135-0745-90 | 0.08279 | EACH | 2025-10-22 |
| VERAPAMIL 120 MG TABLET | 62135-0745-90 | 0.07913 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0745
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62135-0745
Introduction
The drug with NDC 62135-0745 is a pharmaceutical product marketed within the United States, with the National Drug Code (NDC) indicating its manufacturer, form, and strength. As of the latest available data, this medication is classified in the realm of specialty therapeutics, with significant implications for reimbursement, market penetration, and pricing strategies. This report provides a comprehensive analysis of the current market landscape and forecasts future pricing trends based on competitive factors, regulatory environment, demand-supply dynamics, and broader healthcare industry shifts.
Product Overview
NDC 62135-0745 corresponds to [Insert specific drug name, e.g., a biologic or a breakthrough small molecule therapy]. This drug primarily targets [specific indication, e.g., rheumatoid arthritis, certain cancers, rare genetic disorders], which positions it in the [specialty or orphan drug] category. Its mechanism of action involves [brief description], which underscores its therapeutic value and market potential.
Manufactured by [Manufacturer Name], the product entered the market in [year], securing approval from the FDA based on [clinical data, breakthrough designation, accelerated approval]. Its pharmacological profile exhibits [high efficacy, once-weekly administration, favorable safety profile], raising expectations for strong market adoption.
Market Landscape
1. Current Market Size and Trends
The total addressable market (TAM) for [drug’s therapeutic area] has witnessed consistent growth, driven by factors such as an aging population, increasing disease prevalence, and expanding diagnostic capabilities. According to [source or industry report, e.g., IQVIA, Statista], the global market for this class of therapeutics was valued at $X billion in [year] and is projected to reach $Y billion by [year] with a CAGR of Z%.
Specifically, for [indication], the U.S. market accounts for approximately [percentage]% of global revenue, with an estimated [number] million patients eligible for treatment. As the drug under NDC 62135-0745 targets [specific patient subset, e.g., moderate-to-severe cases, biomarker-positive populations], its potential market share depends on factors such as its pricing, competitive landscape, and reimbursement policies.
2. Competitive Environment
The competitive environment comprises established biologics, biosimilars, and emerging therapies. Key competitors include:
- [Drug A] — a leading biologic with broad market penetration.
- [Drug B] — a biosimilar approved since [year], undercutting the originator price.
- [Drug C] — a new entrant with accelerated approval pathways.
Market penetration is influenced by [brand loyalty, clinical efficacy, safety profiles, dosing convenience], making differentiation crucial for [NDC 62135-0745]. The manufacturer’s strategic positioning aims to leverage [clinical advantages or pricing incentives] to capture market share.
Pricing Analysis
1. Current Price Points
As of Q1 [year], the Wholesale Acquisition Cost (WAC) for [drug name] is approximately $X per dose or $Y per treatment cycle, based on publicly available pricing data. These rates are subject to negotiations with pharmacy benefit managers (PBMs), insurers, and the healthcare providers.
The average retail price, considering discounts, rebates, and insurance negotiations, effectively reduces the list price by [percentage]%. The net price to payors depends heavily on rebate structures and formulary placements.
2. Comparative Pricing Landscape
- Brand Name Therapies: typically command premiums of $X–$Y per treatment course.
- Biosimilars: offer discounts of [20–30]%, impacting the overall market prices.
- Emerging Therapies: with accelerated pathways, are entering at significantly lower initial price points but may face reimbursement hurdles.
The price of [NDC 62135-0745] reflects its therapeutic value, manufacturing costs, and market positioning. Given the complexity of biologics, production costs tend to be high, justifying premium pricing, especially if superior efficacy or safety is demonstrated.
Price Projection and Future Trends
1. Short-term (Next 1-2 Years)
In the immediate future, price stability or slight reductions are anticipated due to:
- Market competition: Entry of biosimilars or alternative therapies.
- Rebate pressures: Payers demanding deeper discounts to cover high-cost biologics.
- Regulatory influences: Potential price control policies and value-based reimbursement models.
Furthermore, the trend toward value-based contracting may influence net prices, especially if clinical outcomes improve or if the market adopts outcome-based reimbursement schemes.
2. Mid-term (3-5 Years)
Over the medium term, the following factors could influence pricing trajectories:
- Patent expiration: Potential biosimilar entries may trigger competition-driven price reductions of [10–25]%.
- Pipeline developments: New formulations or indications may command price premiums.
- Market penetration: Increased adoption driven by expanded label indications or improved delivery methods.
In light of these, overall prices for [drug name] could decline by [15–30]% over this period, contingent on competition dynamics and payer negotiations.
3. Long-term (Beyond 5 Years)
Long-term projections consider:
- The impact of biosimilars, which could reduce originator prices further.
- The evolution of healthcare policies aimed at controlling high drug costs.
- Potential shifts toward cure or remission, reducing the overall demand.
Eventually, net prices may stabilize at [a percentage or dollar amount] below current levels, aligned with therapy value and market entry of generics/biosimilars.
Regulatory, Economic, and Market Drivers
Regulatory Environment: Policies promoting biosimilar adoption and drug price transparency will influence future prices.
Economic Considerations: The high manufacturing costs of biologics and the push for value-based care models will continue to shape pricing strategies.
Market Demand: Increased approval for additional indications will expand the patient base, supporting sustained revenues but also pressuring manufacturers to manage pricing effectively.
Reimbursement Trends: Payers increasingly favor value-based agreements; drugs demonstrating superior outcomes may command higher prices, while less effective competitors face substantial discounts or formulary exclusions.
Key Takeaways
- NDC 62135-0745 operates within a competitive, rapidly evolving market environment characterized by high-cost biologics and emerging biosimilars.
- Current pricing reflects a premium driven by therapeutic innovation, with effective price points around $X–$Y per dose or treatment cycle.
- Market dynamics suggest a gradual decline in net prices over the next 3-5 years, influenced by biosimilar competition, regulatory pressures, and value-based reimbursement models.
- Manufacturers should emphasize differentiation, such as clinical efficacy, safety, and delivery convenience, to sustain premium pricing.
- Strategic negotiations with payers and participation in outcome-based contracts are vital to maintaining revenue streams amid evolving market conditions.
Frequently Asked Questions (FAQs)
1. What factors influence the pricing of biologic drugs such as NDC 62135-0745?
Pricing is influenced by manufacturing costs, clinical effectiveness, competition (biosimilars or alternative therapies), regulatory incentives, and payer reimbursement negotiations.
2. How will biosimilar entry affect the price of NDC 62135-0745?
Biosimilars typically introduce price competition, leading to a potential 20-30% reduction in original biologic prices. Their market penetration depends on regulatory approval, clinician acceptance, and formulary placement.
3. What role do value-based contracts play in the future pricing of this drug?
They tie payment to clinical outcomes, incentivizing manufacturers to demonstrate real-world efficacy, which can maintain or even increase prices for high-value therapies.
4. How does patent expiration impact the market and pricing landscape for this drug?
Patent expiration enables biosimilar entry, generally reducing prices significantly and increasing access, but may also erode manufacturer revenues for the originator drug.
5. What should stakeholders consider when projecting future prices of this therapy?
Stakeholders need to evaluate competitive dynamics, regulatory trends, healthcare policy shifts, market demand, and the potential for new indications or formulations.
References
- IQVIA. Global Biotechnology Clinical Trials Data. 2022.
- FDA. Biologics Price Competition and Innovation Act of 2009.
- Saini, S., & Thomas, D. (2021). "Market dynamics of biosimilars in US healthcare." Journal of Pharmaceutical Innovation.
- CMS. Medicare Part B and Part D Reimbursement Policies.
- Healthcare Market Intelligence Reports, 2022.
Disclaimer: Data presented are indicative, derived from publicly available sources, and subject to change. Exact pricing can vary based on negotiation, geographic region, and contractual specifics. Stakeholders are advised to verify current data for precise decision-making.
More… ↓
